(Source: GSK - GlaxoSmithKline plc) 06 May 2015 First programme to evaluate dual HIV maintenance therapy with dolutegravir and rilpivirine London, United Kingdom, 6 May 2015: ViiV Healthcare today announced the start of a phase III clinical trial programme to evaluate the safety and efficacy of dolutegravir (Tivicay®) and rilpivirine (Edurant®1.) as maintenance therapy for adult patients with HIV. The phase III programme comprises two replicate studies evaluating 48 week viral suppression with a two drug regimen combining an integrase inhibitor (dolutegravir) and a non-nucleoside reverse transcriptase inhibitor (rilpivirine) in patients with HIV who have already achieved viral suppression...
↧